With 6.16 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.53 million shares. The 52-week range on XRAY shows that it touched its highest point at $34.91 and its lowest point at $17.21 during that stretch. It currently has a 1-year price target of $20.58. With its current market cap of 3.41 billion, XRAY has annualized dividend of $0.64 while the current yield stands at 3.73%. Beta for the stock currently stands at 0.97.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XRAY was down-trending over the past week, with a drop of -9.50%, but this was down by -12.59% over a month. Three-month performance dropped to -8.63% while six-month performance fell -32.16%. The stock lost -49.09% in the past year, while it has lost -9.64% so far this year. A look at the trailing 12-month EPS for XRAY yields -2.07 with Next year EPS estimates of 2.03. For the next quarter, that number is 0.33. This implies an EPS growth rate of 9.83% for this year and 10.78% for next year. EPS is expected to grow by 11.91% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 32.70%.
Float and Shares Shorts:
At present, 198.80 million XRAY shares are outstanding with a float of 197.55 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XRAY since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $1.85478 being high and $1.8149 being low. For XRAY, this leads to a yearly average estimate of $1.83484. Based on analyst estimates, the high estimate for the next quarter is $0.51 and the low estimate is $0.44. The average estimate for the next quarter is thus $0.47.
